WealthPLAN Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

WealthPLAN Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$24.5K	Buy	+200	New	+$27K	0.01%	442

Other funds holding JAZZ

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

WealthPLAN Partners's JAZZ Position: Q3 2016 in Review

WealthPLAN Partners opened a new position in Jazz Pharmaceuticals (JAZZ) in Q3 2016: 200 shares worth $24.5K. The stake represents 0.01% of the portfolio and ranks #442 among its holdings.

327 funds tracked by Wall St. Rank hold JAZZ as of Q3 2016.

WealthPLAN Partners held 200 shares of Jazz Pharmaceuticals worth $24.5K as of Q3 2016.
Jazz Pharmaceuticals was a new WealthPLAN Partners position in Q3 2016.
Jazz Pharmaceuticals made up 0.01% of WealthPLAN Partners's portfolio in Q3 2016, its #442 holding.
327 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2016.

Based on WealthPLAN Partners's 13F filing for Q3 2016, filed 9 Dec 2016.